Related Experiment Video
Updated: Jun 16, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
New insights on anticancer glucocorticoid receptor modulators: a patent review (2020-present)
Martina Franzin1, Marianna Lucafò2, Debora Curci1
1Department of Translational and Advanced Diagnostics, Institute for Maternal and Child Health, IRCCS "Burlo Garofolo", Trieste, Italy.
Introduction:
Selective glucocorticoid receptor modulators (SGRM) have emerged as promising agents to counteract glucocorticoid‑driven chemoresistance, immune suppression, and poor prognosis in solid tumors by modulating glucocorticoid receptor (GR) signaling without losing anticancer immune activity.
Areas Covered:
This review provides a focused update to a previous patent review on SGRM (2014-2020) by summarizing Espacenet-indexed patent applications published between 2020 and 30 April 2026 (PCT/US2020/055498, PCT/US2021/017259, PCT/US2022/042475) describing anticancer strategies.
Expert Opinion:
Collectively, these patents support SGRM in addition to cytotoxic and immunotherapeutic regimens in solid tumors. Preclinical and early‑phase clinical evidence (phase I/II) describes how GR antagonism, continuously or intermittently, lowers elevated neutrophil-to-lymphocyte ratio (NLR), modulates GR‑target transcriptional signatures, and enhances responses to nab‑paclitaxel and anti‑PD‑1 antibodies. Key limitations of these patents consist of evidence based on still limited clinical sample sizes, requiring confirmation in phase III trials, and on benefit enriched in biologically defined subpopulations. From a clinical perspective, these agents could be realistically integrated into anticancer protocols, as they work synergistically with other chemotherapeutics.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Drug Regulation
Pharmacogenomics: Identification of New Drug Targets
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Targeted Cancer Therapies
There are several types of targeted therapies against specific...